We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Aehr's $22M AI Order Unlock a Bigger WLBI Opportunity?
Read MoreHide Full Article
Key Takeaways
Aehr won a $22M follow-on order for WLBI systems from its lead AI processor customer.
The FOX-XP can test and burn in nine 300mm wafers at once, screening reliability before packaging.
Aehr reported a $100.6M backlog and $60.7M record quarterly bookings at fiscal 2026's end.
Aehr Test Systems, Inc. (AEHR - Free Report) has secured a $22 million follow-on production order from its lead AI processor customer, signaling growing adoption of wafer-level burn-in (WLBI) as AI chips become more complex and costly. The systems are expected to ship over the next six months to the customer’s high-volume manufacturing partner in Taiwan, supporting production of advanced AI training and inference processors.
The order includes multiple FOX-XP systems, FOX WaferPak contactors and Auto Aligners. Each FOX-XP can simultaneously test and burn in nine 300mm wafers, enabling manufacturers to identify early-life reliability issues before chips are packaged. This can help reduce the risk of committing expensive HBM, substrates and interposers to dies that may later fail reliability screening, making WLBI increasingly relevant as AI package complexity rises.
The latest win builds on AEHR’s momentum. In February, the company received a $14 million order from the same lead AI processor customer. It reported a $100.6 million effective backlog at the end of fiscal 2026, while fiscal 2027 revenue guidance of $130-$150 million points to substantial year-over-year growth. Record quarterly bookings of $60.7 million at the fiscal fourth-quarter end also indicate strong demand for its test and burn-in solutions across multiple applications.
Additionally, the company is engaging with additional semiconductor companies and hyperscalers following positive WLBI benchmark results, while targeting applications spanning AI accelerators, CPUs, network processors, memory and HBM. As chip values, power requirements and advanced packaging complexity increase, broader adoption of WLBI could create a meaningful growth avenue for Aehr.
AEHR Faces Stiff Competition
Aehr operates in a highly competitive semiconductor test equipment market, contending with strong rivals such as Teradyne, Inc. (TER - Free Report) and FormFactor, Inc. (FORM - Free Report) .
Teradyne is benefiting from robust AI-related semiconductor testing demand, with its semiconductor test business gaining from higher testing requirements for advanced chips. Strong orders from AI and high-performance computing applications position TER well as chip complexity and testing intensity continue to rise.
FormFactor is benefiting from rising AI and HBM test requirements, with demand for advanced probe cards supported by increasingly complex processors and packaging. FORM’s wafer-level testing capabilities position the company well as semiconductor manufacturers increase testing intensity to improve yield and reliability.
AEHR’s shares have surged 79.5% over the past month, outperforming the broader industry’s 7.9% growth.
Image Source: Zacks Investment Research
Aehr shares are trading at a premium. In terms of the forward 12-month price-to-sales (P/S), AEHR is trading at 27.11X, higher than the industry’s 6.31X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for AEHR’s fiscal 2027 earnings is projected at 70 cents per share, a sharp increase from 3 cents a year ago.
View the Zacks #1 Rank List
Image: Bigstock
Can Aehr's $22M AI Order Unlock a Bigger WLBI Opportunity?
Key Takeaways
Aehr Test Systems, Inc. (AEHR - Free Report) has secured a $22 million follow-on production order from its lead AI processor customer, signaling growing adoption of wafer-level burn-in (WLBI) as AI chips become more complex and costly. The systems are expected to ship over the next six months to the customer’s high-volume manufacturing partner in Taiwan, supporting production of advanced AI training and inference processors.
The order includes multiple FOX-XP systems, FOX WaferPak contactors and Auto Aligners. Each FOX-XP can simultaneously test and burn in nine 300mm wafers, enabling manufacturers to identify early-life reliability issues before chips are packaged. This can help reduce the risk of committing expensive HBM, substrates and interposers to dies that may later fail reliability screening, making WLBI increasingly relevant as AI package complexity rises.
The latest win builds on AEHR’s momentum. In February, the company received a $14 million order from the same lead AI processor customer. It reported a $100.6 million effective backlog at the end of fiscal 2026, while fiscal 2027 revenue guidance of $130-$150 million points to substantial year-over-year growth. Record quarterly bookings of $60.7 million at the fiscal fourth-quarter end also indicate strong demand for its test and burn-in solutions across multiple applications.
Additionally, the company is engaging with additional semiconductor companies and hyperscalers following positive WLBI benchmark results, while targeting applications spanning AI accelerators, CPUs, network processors, memory and HBM. As chip values, power requirements and advanced packaging complexity increase, broader adoption of WLBI could create a meaningful growth avenue for Aehr.
AEHR Faces Stiff Competition
Aehr operates in a highly competitive semiconductor test equipment market, contending with strong rivals such as Teradyne, Inc. (TER - Free Report) and FormFactor, Inc. (FORM - Free Report) .
Teradyne is benefiting from robust AI-related semiconductor testing demand, with its semiconductor test business gaining from higher testing requirements for advanced chips. Strong orders from AI and high-performance computing applications position TER well as chip complexity and testing intensity continue to rise.
FormFactor is benefiting from rising AI and HBM test requirements, with demand for advanced probe cards supported by increasingly complex processors and packaging. FORM’s wafer-level testing capabilities position the company well as semiconductor manufacturers increase testing intensity to improve yield and reliability.
AEHR’s Share Price Performance, Valuation & Estimates
AEHR’s shares have surged 79.5% over the past month, outperforming the broader industry’s 7.9% growth.
Image Source: Zacks Investment Research
Aehr shares are trading at a premium. In terms of the forward 12-month price-to-sales (P/S), AEHR is trading at 27.11X, higher than the industry’s 6.31X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for AEHR’s fiscal 2027 earnings is projected at 70 cents per share, a sharp increase from 3 cents a year ago.
Image Source: Zacks Investment Research
Aehr currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.